| Attribute | Value |
|---|---|
| Category | Disease-Modifying Therapy |
| Target | Pathological Tau (phosphorylated, aggregated) |
| Diseases | Alzheimer's Disease, PSP, CBD, CTE |
| Development Stage | Phase II-III Clinical Trials |
| Route | Intravenous, Subcutaneous |
Tau pathology correlates better with cognitive decline than amyloid-beta in Alzheimer's disease. Tau immunotherapy aims to:
The tau protein is an microtubule-associated protein that stabilizes neuronal microtubules. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated, misfolds, and aggregates into neurofibrillary tangles (NFTs). These pathological tau aggregates spread through connected neural networks, propagating pathology from entorhinal cortex to broader cortical regions following a predictable staging pattern (Braak stages).
Tau immunotherapy represents one of the most promising approaches for disease modification in AD, as it directly targets the pathological species that correlate with clinical symptoms. Unlike amyloid-targeting therapies, tau immunotherapies aim to address the downstream pathology that directly mediates cognitive decline.
Tau immunotherapies work through complementary mechanisms to clear pathological tau and prevent its spread:
Active vaccines such as ACI-35 (AC Immune) use liposome-based platforms to deliver phosphorylated tau peptides, generating antibodies that target multiple pathological tau epitopes. The advantage of active immunization is durable antibody production with fewer infusions, though immune response variability remains a challenge.
Passive immunotherapy with monoclonal antibodies allows precise targeting of specific tau epitopes and more predictable pharmacokinetics. Current development focuses on antibodies targeting various tau regions, including N-terminal, mid-region, and C-terminal epitopes.
| Drug | Company | Target | Stage | Key Notes |
|---|---|---|---|---|
| Semorinemab | Genentech/Roche | Tau (multiple epitopes) | Phase II | Failed in MIDIA trial |
| Gosuranemab | Biogen | N-terminal tau | Phase II | Failed in Tango trial |
| Tilavonemab | AbbVie | N-terminal tau | Phase II | Failed in Phase II |
| JNJ-63733657 | Janssen | Mid-region tau | Phase I | Ongoing |
| Bepranemab | UCB | Mid-region tau | Phase II | Mild efficacy signal |
| ACI-35 | AC Immune | pSer396,404 | Phase Ib | Safety established |
| Lu AF87908 | Lundbeck | Tau aggregates | Phase I | Ongoing |
| Drug | Company | Stage | Mechanism |
|---|---|---|---|
| LMTM | TauRx | Phase III | Methylene blue derivative |
| Sodium phenylbutyrate/taurursodiol | Amylyx | Phase III | Pan-inhibitor |
The field has experienced significant setbacks, with multiple Phase II trials failing to meet primary endpoints:
These failures highlight key challenges in tau immunotherapy development.
Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. 2022. ↩︎
Monteagudo J, et al. Semorinemab efficacy in tauopathies. 2023. ↩︎
Dam T, et al. Gosuranemab in Alzheimer's disease. 2023. ↩︎